Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

MS trials. The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events. Eligible patients in this trial are now receiving dirucotide on an un-blinded basis to the end of their 27th month in the trial.

Licensing and Development Agreement with Lilly

On December 17, 2007, BioMS entered into a licensing and development agreement (the "Agreement") granting Lilly exclusive worldwide rights to dirucotide. The transaction closed on January 25, 2008 and BioMS received an upfront payment of US $87 million. In September 2008, BioMS received a development milestone payment of US $10 million as a result of the positive interim analysis from the DSMB for MASESTRO-01. BioMS has the potential to receive future development and sales milestones up to US $400 million and escalating royalties on sales if dirucotide is commercialized.

Not later than sixty (60) days following receipt of the final written report of the results of the MAESTRO-01 trial, Lilly shall notify BioMS in writing whether Lilly will terminate the Agreement or alternatively Lilly shall bear 100% of any and all continuing development costs incurred by Lilly or BioMS for dirucotide.

HYC750 and BioCyDex

On May 9, 2008, BioMS entered into a Royalty and Assignment Agreement with Orcrist Bio. Inc. for HYC750, a technology based on hyaluronic acid that has a number of potential therapeutic uses and is being developed as a treatment for the side effects of chemotherapy. BioMS held an exclusive worldwide license to HYC750 from the University of Alberta. As a result of the Royalty and Assignment Agreement, BioMS terminated its license with the University of Alberta and the University entered into
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Jan. 14, 2014   Kinaxis ®, provider of RapidResponse ... sales and operations planning ( S&OP ) service, is proud ... , which will be held at the Hilton San Diego ... Kinaxis customer Elisabeth Kaszas , Director of Supply Chain ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Encorium Group, Inc. (Nasdaq:  ENCO), (the "Company"), ... conducting studies in over 30 countries for many ... today announced that, on October 20, 2010, it ... (the "Panel") has determined to delist the Company,s ...
... Inc (OTC: OMCM.OB) today announced that it ranked number ... 500 of the fastest growing technology, media, telecommunications, life ... are based on the percentage of fiscal year revenue ... percent during this period. OmniComm,s CEO, Cornelis ...
... even harder in recent years the influenza A virus has ... Reporting their findings in the journal Science, researchers ... not, and how future treatments can defeat the nasty bug no ... are no longer recommended by the CDC for use against flu. ...
Cached Biology Technology:Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 2Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 3Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 4OmniComm Ranks Number 220 on Deloitte's 2010 Technology Fast 500 for Fastest Growing Companies in North America 2OmniComm Ranks Number 220 on Deloitte's 2010 Technology Fast 500 for Fastest Growing Companies in North America 3Putting a bull's-eye on the flu: Detailing influenza's structure for drug targeting 2
(Date:7/10/2014)... from The University of Texas Health Science Center at ... (IYG), a health education program designed to delay sexual ... dating violence behaviors among minority youth. , According to ... of high school youth are victims of physical dating ... percent are victims of emotional dating violence. Previous studies ...
(Date:7/10/2014)... children and teens living with a cardiac pacemaker, a ... quality of life, reports a study in the July ... , the official journal of the Society for ... published by Lippincott Williams & Wilkins , a ... may function as a protective factor against lower health-related ...
(Date:7/10/2014)... National Cancer Research Centre (CNIO) Macromolecular Crystallography Group ... protein called BuD to DNA in order to ... the researcher who led the study, says the ... the instructions contained in the genome to treat ... study is published in the journal Acta ...
Breaking Biology News(10 mins):It's Your Game ... Keep It Real reduces dating violence among minority youth 2For children with pacemakers, 'self-competence' affects quality of life 2CNIO scientists develop technology to redirect proteins towards specific areas of the genome 2
... Munich have developed a new method for visualizing material ... team led by Bert Nickel has, for the first ... organic thin-film solar cells using laser light for localized ... the scientific journal " Advanced Materials ". "We have ...
... has published research this week in a leading science ... they were raised rather than that likely to maximize ... of habitat selection theory. The paper is published ... on June 26 and includes co-authors Michael Palmer, ...
... significantly challenged as production levels fall due to ... the industry,s competitiveness are being sought. The South ... Resources and Energy (DMITRE) has invited VTT Technical ... study that identifies potential routes by which the ...
Cached Biology News:Organic electronics: Imaging defects in solar cells 2Bioeconomy as a solution for South Australia's declining forest industry 2Bioeconomy as a solution for South Australia's declining forest industry 3
...
... The Varian 500-MS LC Ion Trap ... high-throughput LC/MS analysis where sensitivity, reliability ... 500-MS provides a robust platform for ... mass resolution, and mass stability reflect ...
... modular benchtop fume hood ventilates ... safe indoor release of exhaust. ... organic contaminants. Configurations are available ... options include final HEPA filter, ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Biology Products: